Latham & Watkins advises on Arhaus’ secondary offering of class A common stock by selling stockholders. Arhaus, Inc. (Nasdaq: ARHS), a rapidly growing lifestyle brand and...
You must be a Standard 1 Year member to access this content.
Paul, Weiss represents Savers Value Village, and Latham & Watkins represents the underwriters in the offering. Savers Value Village, Inc. announced the pricing of its upsized...
You must be a Standard 1 Year member to access this content.
Davis Polk represented the underwriters, Cooley represented Arlo and its officers and directors, and Wilson Sonsini represented Netgear. In the California state and federal court securities...
You must be a Standard 1 Year member to access this content.
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Davis Polk is advising Xponential Fitness on the offering, and Latham & Watkins is advising the underwriters involved. Xponential Fitness, Inc. has announced the pricing of...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Deciphera Pharmaceuticals, and Davis Polk advised the joint book-running managers involved in the offering. Deciphera Pharmaceuticals Inc. announced a $135.1 million SEC-registered common stock...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis advised Shoals Technologies Group, while Davis Polk advised the joint book-running managers and representatives of the underwriters in the offering. Shoals Technologies Group,...
You must be a Standard 1 Year member to access this content.
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. RAPT Therapeutics, Inc. executed a $75 million SEC-registered follow-on offering of 4,054,055...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Portland General Electric Company in the offering, while Davis Polk acted as counsel to the representatives of the underwriters. Portland General Electric Company...
You must be a Standard 1 Year member to access this content.
